A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

Srdan Verstovsek, MD, PhD, provides insight on treatment of primary myelofibrosis, including ruxolitinib, and comments on some of the challenges, unmet needs, and future directions in the field.

EP. 1: Introduction: A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis

April 19th 2022

Srdan Verstovsek, MD, PhD, comments on the patient profile and discusses the typical presentation of patients with myelofibrosis (MF).

EP. 2: Clinical Criteria and Tools for Diagnosis of Primary MF

April 19th 2022

An overview of clinical criteria and tools that clinicians use for diagnosis of MF.

EP. 3: Symptom Scoring Systems and Prognostic Risk Models for MF

April 19th 2022

Srdan Verstovsek, MD, PhD, reviews the use of symptom scoring systems and prognostic models for MF risk stratification and treatment selection.

EP. 4: Clinical Factors Impacting Risk Assessment, Prognosis, and Progression

April 19th 2022

A focused discussion on the clinical factors that impact patient prognosis, risk assessment, and disease progression.

EP. 5: Frontline Treatment Options for Primary MF

April 19th 2022

Srdan Verstovsek, MD, PhD, expands upon frontline treatment options for primary MF, including Janus kinase (JAK) inhibitors.

EP. 6: Efficacy Data from Clinical Trials of Ruxolitinib in Primary MF

April 19th 2022

A comprehensive review of key efficacy data from clinical trials on ruxolitinib, including COMFORT-I and COMFORT-II.

EP. 7: Safety Data on Ruxolitinib in Primary MF

April 19th 2022

Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.

EP. 8: JAK Inhibitors: Impact on Symptoms, Quality of Life, and Patient Outcomes in MF

April 19th 2022

Srdan Verstovsek, MD, PhD, reviews how treatment with JAK inhibitors improves symptoms, quality of life, and patient outcomes in primary MF.

EP. 9: Benefits of Clinical Trial Enrollment for Patients with MF

April 19th 2022

A discussion of the benefits of clinical trial enrollment for MF.

EP. 10: Risk of AML and Potential Use of Bone Marrow Transplant in Patients with MF

April 19th 2022

Srdan Verstovsek, MD, PhD, discusses the risk of transformation to acute myeloid leukemia (AML) and the potential use of bone marrow transplant in patients with MF.